



ORIGINAL ARTICLE

Pityriasis Rubra Pilaris: A Multicentric Case Series of 65 Spanish Patients

J. Montero-Menárguez^{a,*}, V. Amat Samaranch^b, L. Puig Sanz^b, R. Ruiz-Villaverde^c, S. Arias-Santiago^d, M. Larrea García^e, D. Ruiz Genao^f, M. Ferrán^g, L. Schneller-Pavelescu^h, C. Romero Ferreiro^{i,j}, R. Rivera Díaz^a

^a Dermatology Department of the Hospital Universitario 12 de Octubre, Madrid, Spain

^b Dermatology Department of Hospital de la Santa Creu i Sant Pau de Barcelona, Spain

^c Dermatology Department of Hospital Universitario San Cecilio de Granada, Spain

^d Dermatology Department of Hospital Virgen de las Nieves de Granada, School of Medicine, Granada University, Instituto de Investigación Biosanitaria IBS, Granada, Spain

^e Dermatology Department of Hospital Universitario de Navarra, Spain

^f Dermatology Department of Fundación Hospital Alcorcón, Spain

^g Dermatology Department of Hospital del Mar de Barcelona, Spain

^h Dermatology Department of Hospital de la Vega Baja de Alicante, Spain

ⁱ Unidad de Soporte Científico, Instituto de Investigación Sanitaria, Hospital Universitario 12 de Octubre, Spain

^j Facultad de Ciencias de la Salud, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain

Received 24 September 2023; accepted 6 February 2024

KEYWORDS

Pityriasis rubra pilaris;
Biologic agents;
Erythroderma

Abstract

Introduction: PRP is a rare entity of unknown etiopathogenesis. Lack of management guidelines makes it a challenge for clinicians.

Objective: To add our experience to increase evidence about PRP.

Methods: We performed a retrospective, descriptive and multicentric study of 65 patients with PRP, being the largest European case series of patients with PRP.

Results: PRP was more frequent in male patients with an average age of 51 years, but erythrodermic forms presented in older patients (average age 61 years).

Six (75%) paediatric patients and ten (60%) non-erythrodermic adults controlled their disease with topical corticosteroids. On the contrary, 26 (68%) erythrodermic patients required biologic therapy as last and effective therapy line requiring an average of 6.5 months to achieve complete response.

* Corresponding author.

E-mail address: julia.montero.menarguez@gmail.com (J. Montero-Menárguez).

<https://doi.org/10.1016/j.ad.2024.02.019>

0001-7310/© 2024 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVE

Pitiriasis rubra
pilaris;
Tratamiento
biológico;
Eritrodermia

Conclusion: Our study showed a statistical difference in terms of outcome and response to treatment between children or patients with limited disease and patients who develop erythroderma.

© 2024 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Pitiriasis rubra pilaris: serie de casos multicéntrica de 65 pacientes españoles

Resumen

Introducción: La pitiriasis rubra pilaris (PRP) es una entidad rara de etiopatogenia desconocida. La falta de guías clínicas la convierte en un desafío para los clínicos.

Objetivo: Contribuir con nuestra experiencia a aumentar la evidencia disponible sobre esta entidad.

Método: Realizamos un estudio retrospectivo, descriptivo y multicéntrico de 65 pacientes con PRP, siendo la serie de casos europea más grande de pacientes con PRP.

Resultados: La PRP fue más frecuente en los varones con una edad promedio de 51 años, pero las formas eritrodérmicas se presentaron en pacientes de mayor edad, en torno a los 61 años.

Seis (75%) de los pacientes pediátricos y 10 (60%) de los adultos no eritrodérmicos controlaron su enfermedad con corticoides tópicos. Por el contrario, 26 (68%) de los pacientes eritrodérmicos necesitaron terapia biológica como última línea terapéutica eficaz; requiriendo un promedio de 6,5 meses para lograr una respuesta completa.

Conclusión: Nuestro estudio mostró una diferencia estadística en términos de resultado y respuesta al tratamiento entre niños o pacientes con enfermedad limitada y pacientes que desarrollan eritrodermia.

© 2024 AEDV. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Pityriasis rubra pilaris (PRP) is an uncommon inflammatory disease, traditionally considered as a reactive dermatosis.¹⁻³ It appears in a bimodal age distribution in the first and fifth decades of life and equal frequency between sexes, as follicular hyperkeratotic salmon-coloured papules and plaques. Some patients develop erythroderma leaving islands of non-involved skin.^{1,2}

Diagnosis requires a good clinicopathological correlation. Alternating orthokeratosis and parakeratosis known as “checkerboard pattern” is the main histopathological feature. Treatment options include a variety of drugs such as topical corticosteroids, oral retinoids, immunosuppressors and biologic agents.^{2,4-6} PRP is believed to share cytokine environment with psoriasis.⁷

There are no management guidelines and current scientific evidence is limited to case reports and case series. Consequently, management of PRP represents a challenge.

Objective

To describe clinicopathological and demographic features of PRP patients and analyze treatment modalities.

Methods

A multicentre retrospective observational study was carried out in eight Spanish hospitals including patients with clinicopathological diagnosis of PRP, treated during 20 years

(between January 2002 and February 2022). Variables were collected by each centre in an anonymous database. Paediatric sample was defined as patients under 16 years old. We used body surface area (BSA) to evaluate treatment response and considered complete response as BSA <3%. A descriptive statistical analysis was performed, using the mean and standard deviation (SD) for quantitative variables and absolute and relative frequencies for qualitative variables. The contrasts of hypotheses in the qualitative variables were carried out using the Chi-square test or Fisher’s exact test and for quantitative variables using the Student’s *t*-test. A *p*-value <0.05 was considered statistically significant. All analyses were performed with the statistical software Stata® (StataCorp, College Station, Texas) version 16 for Windows. The study was conducted following the Declaration of Helsinki and was approved by the Medical Ethics Committee of the Hospital 12 de Octubre (No: 22/233).

Results

Epidemiological, clinical, histopathological and therapeutic results can be found in [Table 1](#).

Epidemiology

A total of 65 patients were included. At the time of enrolment, eight children were an average of 7.8 years old and four (50%) were female.

Thirty-nine male patients represented 68% of the adult sample and 40 of them (70%) developed erythroderma, but



Figure 1 Non-involved skin islands in a patient with PRP.



Figure 2 Palmoplantar keratoderma in a patient with PRP.

only one child. Mean age was older in erythrodermic adults (61 years) when compared to non-erythrodermic adults (51 years, p -value = 0.015).

Triggers and comorbidities

A possible trigger was reported by 13 (20%) patients: previous infection in seven (12%) adults and two (25%) children; and drugs in four (7%) adults.

Infections in children were all upper airway infections. Among adult patients we did not collect specific microbiological agents data.

Four (7%) of our adult patients had concomitant neoplasia and five (9%) autoimmune comorbidities.

Clinical findings

The most frequent clinical features were non-involved skin islands ($n = 49$, 83%) and palmoplantar (PP) keratoderma ($n = 53$, 85%), which were also more frequent in erythrodermic patients (Figs. 1 and 2). The difference was statistically significant for PP keratoderma (p -value 0.029). However, children presented only in two (29%) and four (50%) of the cases with non-involved skin islands and PP keratoderma respectively.

Forty-one (63%) of patients reported pruritus, but only two (25%) children and 39 (68%) of the adults (p -value 0.017).

Other clinical features are detailed in Table 1.

Histology

Most frequent histological findings were alternating ortho- and parakeratosis ($n = 41$, 67%) and irregular epidermic hyperplasia ($n = 36$, 59%).

Treatment

Mean treatment duration was 2.4 months in children, 8 months in non-erythrodermic adults and 21.4 months in erythrodermic adults. Time to BSA <3% was shorter and number of treatments lower in children and non-erythrodermic adults than their counterparts (Table 1).

All of the children were initially treated with topical corticosteroids. Only one of them required acitretin. One developed erythroderma and needed ustekinumab to control the disease. Complete response (CR) was achieved in seven (88%) of the children.

Non-erythrodermic adults ($n = 17$, 30%) were successfully managed with topical therapy in nine (60%) patients. Six were treated with systemic agents (acitretin in three and phototherapy in one patient). Only five patients required a biologic agent. CR was achieved in 13 (76%) of non-erythrodermic adults.

On the other hand, 29 (71%) erythrodermic patients were initially managed with systemic agents such as acitretin in twelve (30%) of the cases or methotrexate in ten (25%) of the patients, phototherapy in seven (18%) and one patient began with ustekinumab. Last effective treatment included a variety of drugs (Table 1) and complete response was achieved in 26 (68%) of patients. Biologic therapy was required at some point by 31 (68%) of patients and ustekinumab was the most frequently used.

Limitations

Our study has several limitations. First, our data was collected retrospectively with a relatively small sample size. In addition, there are no standardized diagnostic criteria of PRP or severity scales to assess treatment response. Lastly, the availability of new biologic therapies over the course of the last decade may have exerted some influence on therapeutic results of patients diagnosed in the latest years.

Discussion

This study presents detailed demographic, clinicopathologic and treatment data in 65 patients diagnosed of PRP. To the best of our knowledge, this is the largest European case series of patients with PRP.

Our study demonstrated predominance in adult male patients ($n = 39$, 68%), which differs from data on literature maintaining equal sex distribution.^{1–4} Bimodal distribution was consistent with literature,^{1–4} but strikingly adult patients presenting with erythroderma were on average 10 years older (p -value <0.05).

Multiple case reports claim possible causality between malignancies or autoimmune disorders and PRP.^{1,7} However, our adult patients showed a low frequency of autoimmune comorbidities (9%) and malignancies (6%), suggesting that their frequency may not differ from general population and screening procedures should be guided by history and physical examination.

Infectious and pharmacological agents have usually been described to trigger PRP.^{1,2} Interestingly, 25% of our children reported an infectious trigger but in only 6% of erythroder-

Table 1 Detailed patient's characteristics.

	Total	Children	Adults	Non-erythrodermic adults	Erythrodermic adults	
<i>N</i>	65	8	57	17	40	
<i>Age</i>	51.8 (21.5)	7.8 (4.7)	58 (14.5)	51 (13.4)	61 (14.1)*	0.015
<i>Sex</i>						
Female	22 (34%)	4 (50%)	18 (32%)	12 (71%)	27 (68%)	
Male	43 (66%)	4 (50%)	39 (68%)	5 (29%)	13 (33%)	
<i>Trigger</i>						
Infection	9 (14%)	2 (25%)	7 (12%)	1 (6%)	6 (15%)	
Drug	4 (6%)	0	4 (7%)	1 (6%)	3 (8%)	
<i>Comorbidities</i>						
Autoimmune	5 (8%)	0	5 (9%)	1 (6%)	4 (10%)	
Malignancies	4 (6%)	0	4 (7%)	1 (6%)	3 (8%)	
<i>Clinical findings</i>						
Upper body initial lesions	42 (66%)	3 (38%)	39 (68%)	10 (59%)	29 (45%)	
Pruritus	41 (63%)	2 (25%)	39 (68%)*	9 (53%)	30 (75%)	
Nail involvement	25 (38%)	1 (13%)	24 (42%)	5 (29%)	19 (48%)	
Erythroderma	41 (63%)	1 (13%)	40 (70%)	100%	0	
Non-involved skin islands	49 (83%)	2 (29%)	47 (90%)	10 (77%)	36 (95%)	
PP keratoderma ^a	53 (82%)	4 (50%)	49 (86%)	12 (71%)	37 (93%)*	
Intertriginous involvement	20 (31%)	2 (25%)	18 (32%)	7 (41%)	11 (28%)	
<i>Histopathologic findings</i>						
Alternating ortho- and parakeratosis	41 (67%)	3 (60%)	38 (68%)	11 (65%)	27 (69%)	
Irregular hyperplasia of the epidermis	36 (59%)	2 (40%)	34 (61%)	8 (47%)	26 (67%)	
Peri-infundibular parakeratosis	18 (35%)	0	18 (37%)	5 (33%)	13 (38%)	
<i>No. of biopsies</i>	1.5 (0.8)	1 (0)	1.5 (0.8)	1.3 (0.6)	1.59 (0.9)	
<i>No. of treatments</i>	2.2 (1.4)	0.8 (0.7)*	2.4 (1.3)	1.6 (1.3)	2.7 (1.3)*	
<i>First line treatments</i>						
Acitretin	15 (25%)	0	15 (27%)	3 (20%)	12 (30%)	
Ciclosporin	6 (10%)	0	6 (11%)	1 (7%)	5 (13%)	
Topical corticosteroids	18 (30%)	8 (100%)	13 (24%)	9 (60%)	4 (10%)	
Isotretinoin	2 (3%)	0	2 (4%)	1 (7%)	1 (3%)	
Methotrexate	10 (17%)	0	10 (18%)	0 (0%)	10 (25%)	
NB-UVB ^b	5 (8%)	0	5 (9%)	1 (7%)	4 (10%)	
UVA	1 (2%)	0	1 (2%)	0 (0%)	1 (3%)	
UVB	2 (3%)	0	2 (4%)	0 (0%)	2 (5%)	
Ustekinumab	1 (2%)	0	1 (2%)	0 (0%)	1 (3%)	
<i>Last line effective treatments</i>						
Topical corticosteroids	19 (30%)	6 (75%)	13 (23%)	10 (59%)	3 (8%)	
Acitretin	6 (9%)	1 (13%)	5 (9%)	2 (12%)	3 (8%)	
Methotrexate	5 (8%)	0	5 (9%)	1 (6%)	4 (10%)	
Apremilast	3 (5%)	0	3 (5%)	0 (0%)	3 (8%)	
Etanercept	1 (2%)	0	1 (2%)	0 (0%)	1 (3%)	
Infliximab	4 (6%)	0	4 (7%)	1 (6%)	3 (8%)	
Ixekizumab	4 (6%)	0	4 (7%)	0 (0%)	4 (10%)	
Risankizumab	1 (2%)	0	1 (2%)	0 (0%)	1 (3%)	
Secukinumab	3 (5%)	0	3 (5%)	1 (6%)	2 (5%)	
Ustekinumab	15 (23%)	1 (13%)	14 (25%)	2 (12%)	12 (31%)	
Brodalumab	3 (5%)	0	3 (5%)	0 (0%)	3 (8%)	
<i>Complete response**</i>	46 (73%)	7 (88%)	39 (71%)	13 (76%)	26 (68%)	
<i>Time to BSA <3% (months)</i>	5 (3.4)	2.4 (0.8)*	5.4 (3.5)	3.2 (2)	6.5 (3.5)	
<i>Treatment duration</i>	16.5 (23.9)	2.4 (0.6)	18.1 (24.8)	8.0 (6.9)	21.5 (27.6)*	

^a PP keratoderma: palmoplantar keratoderma.

^b NB-UVB: Narrowband UVB.

* Differences between adults and children or erythrodermic and non-erythrodermic patients were statistically significant (p -value <0.05). Results are formulated in mean (standard deviation) or absolute numbers (percentage).

** Complete response is defined as BSA <3%.

mic adults a culprit drug was demonstrated. This supports the idea of PRP as a multifactorial disease, in which environmental factors play a role but are not necessary for the development of the disease.

The most frequent histological feature was alternating ortho- and parakeratosis, matching literature data. However, histology can be unspecific and often diagnosis is predominantly guided by characteristic clinical features.¹⁻⁴ Sixty-six percent of our patients initiated lesions on the upper body, which is consistent with the cephalocaudal progression classically described.¹⁻⁴ Interestingly, 94% of our erythrodermic patients presented PP keratoderma (*p*-value 0.02).

Fouarge et al.,⁸ already proposed PP keratoderma as a possible factor for resistance to an IL-23/p19 antagonist. In our opinion, it may be a progression marker, and could help identify patients at a higher risk of developing erythrodermic forms of PRP.

Seventy-five percent of the paediatric patients and 60% of the non-erythrodermic adults controlled their disease with topical corticosteroids. Good response to topical therapy was already described in paediatric PRP,⁹ but we assume it is extendible to adults with localized disease. However, most of erythrodermic patients (68%) required biologic therapy as last and effective therapy line. Among them, 68% achieved complete response but after an average of 6.5 months of treatment. They usually receive more lines of treatment (mean 2.7) than patients with localized lesions and may benefit from a more invasive and early approach.

Conclusion

In conclusion, our study reported that PRP may be more frequent in men and erythrodermic forms could appear in older patients. There was no clear association with cancer or autoimmune diseases in our patients. PP keratoderma may be a marker of progression to erythroderma. Children and adults with localized disease in our sample usually respond to topical corticosteroids. On the contrary, erythrodermic patients received multiple therapy lines, needed an average of 6.5 months and a biologic agent to control their disease. Further studies are required to investigate this challenging disease.

Patient's consent

The patients in this manuscript have given written informed consent to publication of their case details.

Funding

None declared.

Conflicts of interest

- Dr Ruiz Genao has been reimbursed by Almirall, Pfizer, Janssen, Amgen, Abbvie, Lilly, UCB, Novartis and Leo-Pharma for advisory services and conferences.
- L. Puig has perceived consultancy/speaker's honoraria from and/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer, Sandoz, Sanofi, and UCB.

Acknowledgments

The authors confirm that the manuscript has been submitted solely to this journal and is not submitted, in press, or published in any language elsewhere. Each author has participated sufficiently in the work to take public responsibility of the content.

References

1. Wang D, Chong VC, Chong WS, Oon HH. A review on pityriasis rubra pilaris. *Am J Clin Dermatol*. 2018;19:377–90, <http://dx.doi.org/10.1007/s40257-017-0338-1>.
2. Roenneberg S, Biedermann T. Pityriasis rubra pilaris: algorithms for diagnosis and treatment. *J Eur Acad Dermatol Venereol*. 2018;32:889–98, <http://dx.doi.org/10.1111/jdv.14761>.
3. Ross NA, Chung HJ, Li Q, Andrews JP, Keller MS, Uitto J. Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients. *JAMA Dermatol*. 2016;152:670–5, <http://dx.doi.org/10.1001/jamadermatol.2016.0091>.
4. Kromer C, Sabat R, Celis D, Mössner R. Systemische Therapien bei Pityriasis rubra pilaris: eine systematische Übersicht. *J Dtsch Dermatol Ges*. 2019;17:243–60, <http://dx.doi.org/10.1111/ddg.13718>.
5. Ringin SA, Daniel BS. Treatment modalities for pityriasis rubra pilaris subtypes: a review. *J Dermatolog Treat*. 2022;33:587–8, <http://dx.doi.org/10.1080/09546634.2020.1729954>.
6. Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: a review of the literature. *J Am Acad Dermatol*. 2018;79, <http://dx.doi.org/10.1016/j.jaad.2018.03.036>, 353–359.e11.
7. Kamarachev J, Grozdev I, Darlenski R, Tsankov N. Pityriasis rubra pilaris as a systemic disease. *Clin Dermatol*. 2019;37:657–62, <http://dx.doi.org/10.1016/j.clindermatol.2019.07.030>.
8. Fouarge AL, Cuvelier M, Roquet-Gravy C, de Montjoye L, Baeck M. Successful treatment of pityriasis rubra pilaris with risankizumab, a IL-23/p19 antagonist. *J Eur Acad Dermatol Venereol*. 2023;37:e106–9, <http://dx.doi.org/10.1111/jdv.18516>.
9. Yang CC, Shih IH, Lin EL, Yu YS, Chiu HC, Huang PH, et al. Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan. *J Am Acad Dermatol*. 2008;59:943–8, <http://dx.doi.org/10.1016/j.jaad.2008.07.054>.